159
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project

ORCID Icon, , ORCID Icon, , ORCID Icon, , , , , , , , , ORCID Icon & ORCID Icon show all
Pages 395-407 | Received 17 Oct 2023, Accepted 09 May 2024, Published online: 03 Jun 2024

Figures & data

Table 1 Individual IMID-Specific Algorithms Retrieved from the Literature

Figure 1 Flow chart of incident biological drug users included in the study.

Abbreviations: ETP, Electronic therapeutic plans; ID, Index date; IMID, Immune-mediated inflammatory disease.
Figure 1 Flow chart of incident biological drug users included in the study.

Table 2 Validity Estimates of the META-Algorithm According to the Main Analysis

Figure 2 Percentage of indications of use assigned by the META-algorithm against the reference standard.

Abbreviations: CD, Crohn’s disease; PsO, Psoriasis; PsA, Psoriatic arthritis; RA, Rheumatoid arthritis; SpA, Spondyloarthritis; UC, Ulcerative colitis.
Figure 2 Percentage of indications of use assigned by the META-algorithm against the reference standard.

Figure 3 Frequency (%) of indication of use stratified by single biological drug across regions (Apulia, Latium, Lombardy, and Veneto).

Note: *Other IMIDs: HS and Uveitis.
Abbreviations: CD, Crohn's disease; UC, Ulcerative colitis; RA, Rheumatoid arthritis; PsO, Psoriasis; PsA, Psoriatic arthritis; SpA, Spondyloarthritis.
Figure 3 Frequency (%) of indication of use stratified by single biological drug across regions (Apulia, Latium, Lombardy, and Veneto).

Data Sharing Statement

All available data are included in the manuscript and in the Supplementary Materials.